NCT01466660

Who might be able to join this trial:

• You have been diagnosed with advanced lung cancer (stage IIIB or IV) of a specific type called adenocarcinoma, confirmed by a lab test.
• Your tumour has been tested and found to have a specific gene change (mutation) in the EGFR gene, specifically called Del19 and/or L858R.
• You have at least one tumour that can be measured on a scan.
• You are generally well enough to carry out light activity and care for yourself (your doctor will assess this using a standard scale).
• You are 18 years of age or older.
• Your liver, kidneys, and blood cell counts are within acceptable ranges based on recent blood tests.

Who may not be able to join:

• You have already had chemotherapy for advanced (stage IIIB or IV) lung cancer (earlier chemotherapy for a different stage may be allowed if it was more than 12 months ago).
• You have previously been treated with medicines that target the EGFR gene (small molecule drugs or antibodies).
• You had major surgery within the last 4 weeks.
• You currently have active cancer spread to the brain.
• You have cancer that has spread to the membranes surrounding the brain or spinal cord.
• You have or have had another type of cancer, with some exceptions such as certain treated skin cancers or cancers that have been fully in remission for more than 3 years (confirm with trial site).
• You have a known pre-existing lung condition called interstitial lung disease.
• You have significant heart or cardiovascular problems, as assessed by your doctor.
• Your heart's pumping function is below the normal range for the hospital running the trial.
• You are a woman who could become pregnant, or a man who could father a child, and you are unwilling to use reliable contraception or remain abstinent during the trial and for at least 2 months after treatment ends.
• You are currently pregnant or breastfeeding.
• You have active hepatitis or are known to carry the HIV virus.
• You are taking certain medications that are not permitted alongside the trial drugs afatinib or gefitinib (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.